Business Context and Reporting Period
This Form 8-K Current Report was filed by Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) on October 21, 2024. The filing reports a corporate governance event: the appointment of a new director to the Board of Directors.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
The primary material change reported is the appointment of Alison Moore, Ph.D., as a Class III director and a member of the Technical Operations Committee. Dr. Moore brings significant industry experience, having previously served as Chief Technical Officer at Allogene Therapeutics and in various senior roles at Amgen and Genentech.
Compensation and Governance Details
- Annual Cash Retainer: $40,000 for Board service and an additional $15,000 for Technical Operations Committee service.
- Initial Equity Grant: An option to purchase 27,500 shares of common stock. One-third vested immediately upon grant, with the remainder vesting monthly over two years.
- Future Grants: Automatic annual option grants of 13,750 shares on the date of each annual meeting, vesting in full after one year or at the next annual meeting.
- Change in Control: All option grants vest in full upon a change in control.
Investor Verification Checklist
- Verify the impact of the new director's expertise on the company's technical operations and pipeline development.
- Review the company's 2024 Equity Incentive Plan to understand the specific vesting conditions and dilution implications.
- Confirm the total number of outstanding options and shares reserved for issuance under the compensation policy.
- Check for any subsequent filings regarding the company's cash position, as this 8-K does not address liquidity.